Evidence map›Paper›PMID 16960113›Full record

ArticleClinical and vaccine immunology : CVI2006

Unique model of dormant infection for tuberculosis vaccine development.

Suely S Kashino, Pamela Ovendale, Angelo Izzo, Antonio Campos-Neto

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Mouse Models forPathogens (Basel, Switzerland) · 2022
    Review
  3. Microorganisms · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Current and novel approaches to vaccine development against tuberculosis.Frontiers in cellular and infection microbiology · 2012
    Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Suely S KashinoThe Forsyth Institute, 140 The Fenway, Boston, MA, 02115-3799, USA.
Pamela Ovendale
Angelo Izzo
Antonio Campos-Neto
Corixa Corporation · USColorado State University · US

Funding

VACCINE DEVELOPMENT IN TUBERCULOSISR01AI043528 · NIAID · INFECTIOUS DISEASE RESEARCH INSTITUTE · PI CAMPOS-NETO, ANTONIO · 2000 to 2004
$1.4M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR011244 · NCRR · FORSYTH INSTITUTE · PI STASHENKO, PHILIP · 1996 to 1996
–
NCRR NIH HHS C06RR11244NIAID NIH HHS AI 43528NIAID NIH HHS R01 AI043528PHS HHS 1-A125174
6 · The paper itself

Abstract

Most individuals exposed to Mycobacterium tuberculosis become infected but hinder the infectious process in dormant foci, known as latent tuberculosis. This limited infection usually stimulates strong T-cell responses, which provide lifelong resistance to tuberculosis. However, latent tuberculosis is still poorly understood, particularly because of the lack of a reliable animal model of dormant infection. Here we show that inoculation of mice with a unique streptomycin-auxotrophic mutant of Mycobacterium tuberculosis recapitulates dormant infection. The mutant grows unimpaired in the presence of streptomycin and no longer grows but remains viable for long periods of time after substrate removal, shifting from the log growth phase to the latent stage, as indicated by augmented production of alpha-crystallin. Mice challenged with the mutant and inoculated with streptomycin for approximately 3 weeks developed a limited infection characterized by a low bacteriological burden and the presence of typical granulomas. After substrate withdrawal, the infection was hindered but few microorganisms remained viable (dormant) in the animals' tissues for at least 6 months. In addition, the animals developed both potent T-cell responses to M. tuberculosis antigens, such as early culture filtrate, Ag85B, and ESAT-6, and resistance to reinfection with virulent M. tuberculosis. Therefore, infection of mice or other animals (e.g., guinea pigs) with M. tuberculosis strain 18b constitutes a simple and attractive animal model for evaluation of antituberculosis vaccines in the context of an M. tuberculosis-presensitized host, a prevailing condition among humans in need of a vaccine.

Indexed as

alpha-CrystallinsAnimalsAntigens, BacterialBCG VaccineCD11b AntigenCD4 AntigensCD8 AntigensColony Count, MicrobialDisease Models, AnimalImmunohistochemistryIn Vitro TechniquesLungMiceMice, Inbred BALB CMutationMycobacterium tuberculosisalpha-CrystallinsAntigens, BacterialBCG VaccineCD11b AntigenCD4 AntigensCD8 AntigensTuberculosis Vaccines

Identifiers

PMID16960113
PMCPMC1563568
OpenAlexW2124569362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.